期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨治疗MDS/AML1例报告 被引量：2

A case of HDS/AML treated with decitabine
下载PDF
导出
摘要 骨髓增生异常综合征（myelodysplasticsyndrome,MDS）是一组起源于造血干细胞水平的恶性造血紊乱性疾病,
作者 谷伟
机构地区 武警江苏总队一支队卫生队
出处 《武警医学院学报》 CAS 2012年第1期58-59,共2页 Acta Academiae Medicinae CPAPF
关键词 地西他滨 骨髓增生异常综合征 急性髓细胞白血病
分类号 R730.263 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Jackson G,Taylor P,Smith GM,et al.A multicentre,open,non-comparative phase I study of a combination offludarabine and granulocyte colony-stimulating factor inrelapsed and refractory acute myeloid leukemia and de novorefractory anemia with excess of blasts in transformation[J].Br J Haematol,2001,112(1):127-137.
  • 2Ganser A,Heil G,Seipelt G,et al.Intensive chemotherapywith idarubicin,ara-C,etoposide,and M-AMSA followed byimmunotherapy with interleukin-2 for myelodysplasticsyndrome and high-risk acute myeloid leukemia(AML)[J].Ann Hematol,2000,79(1):30-32.
  • 3Lbbert M,Minden M.Decitabinein acute myeloid leukemia[J].Semin Hemato1,2005,42(3):38-42.
  • 4Lbbert M,Rueer B,Schmid M,et al.Contiuned two-dosedecitabine(DAC)is an active first-line treatment of olderAML patients:First results of a multicenter phase I study[J].Blood,2005,106:527.
  • 5Cashen A,Shah A,Helget A,et al.A phase I phamacokinetictrial of decitabine administered as a 3-hour infusion topatients with acute myelogenous leukemia(AML)ormyelodysplastic syndrome(MDS)[J].Blood,2005,106(11):527.

同被引文献54

  • 1张建东,张育,顾健.骨髓增生异常综合征的药物治疗[J].实用临床医药杂志,2005,9(3):104-108. 被引量：2
  • 2Greenberg P, Cox C, LeBeau MM, et al. international scoring system for evaluating prognosis in myelodysplastic syndromes [ J ]. Blood, 1997,89(6) :2079 -2088.
  • 3Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome [ J ]. Cancer, 2010, 116 (9) :2174 -2179.
  • 4Guillermo GM. Myelodysplastic syndromes:2011 update on diagno- sis, risk-stratification, and management [ J ]. Am J Hemato1,2011,86 (6) :491 -498.
  • 5Takatoku M, Uehiyama T,Okamoto S,et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload oil morbidity/mortality [ J ]. Eur J Haemato1.2007.78 (6) :487 - 494.
  • 6Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron o- verload and transfusion dependency on survival and leukemic evolu- tion in patients with myelodyspl.astic syndrome [ J ]. Blood, 2008, 112:640.
  • 7Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology:myelodysplastic syndromes[ J]. J Natl Corn-pr Cane Netw,2011,9(1) :30 -56.
  • 8高绍华,李宝军.急性白血病化疗前后血清叶酸、铁蛋白水平变化及其临床意义[J].武警后勤学院学报,2009,18(5):446-447.
  • 9Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes:Results of six cross- sectional physician surveys [ J]. J Natl Cancer Inst, 2008, 100 (21) :1542 - 1551.
  • 10Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating a- gents in the treatment of anemia in myelodysplastic syndromes : A meta-analysis [ J ]. Ann Hemato1,2008,87 (7) :527 - 536.

引证文献2

二级引证文献1

武警医学院学报
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部